Emerging within the UK, retatrutide, a new peptide , is sparking considerable excitement within the scientific community regarding its promise for physique management . This dual GIP and GLP-1 receptor agonist appears to deliver a substantial improvement over current therapies, showing promising results in preliminary clinical trials . Researchers